Search Results
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by H H Milioli in
Google Scholar
PubMed
Search for other papers by S Alexandrou in
Google Scholar
PubMed
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by E Lim in
Google Scholar
PubMed
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by C E Caldon in
Google Scholar
PubMed
refractory to standard chemotherapies. As a result, biomarkers of therapeutic resistance and therapeutic targets are required to identify and treat these patients. Cyclins E/CDK complexes are acutely responsive to estrogen and anti-estrogens ( Caldon et al
Search for other papers by Joseph M Shulan in
Google Scholar
PubMed
Search for other papers by Leonid Vydro in
Google Scholar
PubMed
Search for other papers by Arthur B Schneider in
Google Scholar
PubMed
Search for other papers by Dan V Mihailescu in
Google Scholar
PubMed
( NCRP 2009 ). While several studies have attempted to identify biomarkers that are predictive of the likelihood of malignancy in patients with thyroid nodules in the general population, the data correlating these factors in radiation-induced thyroid
Search for other papers by Fei Han in
Google Scholar
PubMed
Search for other papers by Wen-bin Liu in
Google Scholar
PubMed
Search for other papers by Jian-jun Li in
Google Scholar
PubMed
Search for other papers by Ming-qian Zhang in
Google Scholar
PubMed
Search for other papers by Jun-tang Yang in
Google Scholar
PubMed
Search for other papers by Xi Zhang in
Google Scholar
PubMed
Search for other papers by Xiang-lin Hao in
Google Scholar
PubMed
Search for other papers by Li Yin in
Google Scholar
PubMed
Search for other papers by Cheng-yi Mao in
Google Scholar
PubMed
Search for other papers by Xiao Jiang in
Google Scholar
PubMed
Search for other papers by Jia Cao in
Google Scholar
PubMed
Search for other papers by Jin-yi Liu in
Google Scholar
PubMed
, identification of new prognostic biomarkers and chemotherapeutic indicators is of great importance to improve therapeutic methods and prolong the survival of patients with ovarian cancer. Sox30, a member of Sox transcription factor, is always considered to be
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Search for other papers by Yuanliang Yan in
Google Scholar
PubMed
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Search for other papers by Qiuju Liang in
Google Scholar
PubMed
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Search for other papers by Yuanhong Liu in
Google Scholar
PubMed
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Search for other papers by Shangjun Zhou in
Google Scholar
PubMed
Search for other papers by Zhijie Xu in
Google Scholar
PubMed
death, which could be mitigated via ICI-based combination therapies ( Wang et al. 2021 , Viscardi et al. 2022 ). Despite these encouraging benefits, only a few BC patients have achieved a durable response to ICIs in clinical practice. Biomarkers
Research Laboratory of Pediatrics and Nephrology, Laboratory of Functional Genomics, 2nd Department of Pathology, Center for Biological Sequence Analysis, Children's Hospital, Hungarian Academy of Sciences, Budapest, Hungary
Search for other papers by Balázs Győrffy in
Google Scholar
PubMed
Search for other papers by András Lánczky in
Google Scholar
PubMed
Research Laboratory of Pediatrics and Nephrology, Laboratory of Functional Genomics, 2nd Department of Pathology, Center for Biological Sequence Analysis, Children's Hospital, Hungarian Academy of Sciences, Budapest, Hungary
Search for other papers by Zoltán Szállási in
Google Scholar
PubMed
related to patient outcome. To date, only two biomarkers have been approved by the Food and Drug Administration (FDA) for monitoring patients with EOC: CA125 ( MUC16 ; Gadducci et al . 1995 , 2004 , Cooper et al . 2002 , Riedinger et al . 2006
Search for other papers by Kjell Oberg in
Google Scholar
PubMed
commonly present late in the disease course with imageable metastases identified per chance or when studies are ordered for symptoms attributable to tumour growth rather than hormone production ( Metz & Jensen 2008 , Vinik et al . 2009 ). Biomarker
Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia, USA
Search for other papers by Jennifer W Carlisle in
Google Scholar
PubMed
Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA
Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA
Search for other papers by Caroline S Jansen in
Google Scholar
PubMed
Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia, USA
Search for other papers by Mehmet Asim Bilen in
Google Scholar
PubMed
Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA
Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA
Search for other papers by Haydn Kissick in
Google Scholar
PubMed
functioning as a biomarker of response to immunotherapy. Examples of successful use of this tactic and the potential impact of COVID-19 on this approach is reviewed subsequently. Expression of programmed cell death protein 1 (PD-1) on T cells during chronic
INSERM UMR1048, I2MC, Toulouse, France
Search for other papers by Jacques Amar in
Google Scholar
PubMed
Search for other papers by Jeremy Brunel in
Google Scholar
PubMed
Search for other papers by Catherine Cardot Bauters in
Google Scholar
PubMed
Laboratory of Biochemistry and Molecular Biology, IFB-CHU, Toulouse, France
Search for other papers by Virginie Jacques in
Google Scholar
PubMed
Department of Cardiology Toulouse University, Hôpital Rangueil, Toulouse, France
Search for other papers by Clément Delmas in
Google Scholar
PubMed
Univ. Lille, Inserm, CHU Lille, U1286 – Infinite – Institute for Translational Research in Inflammation, Lille, France
Search for other papers by Marie-Françoise Odou in
Google Scholar
PubMed
Laboratory of Biochemistry and Molecular Biology, IFB-CHU, Toulouse, France
Search for other papers by Frédérique Savagner in
Google Scholar
PubMed
. Discussion The main finding of the study was that 2CDel322–325 polymorphism was a biomarker of the risk of CIC in patients with PPGL. Some studies have previously identified such a relationship between one SNP and acute events ( Kim & Jeong 2020 , Li et
Search for other papers by Mark Kidd in
Google Scholar
PubMed
Search for other papers by Ignat Drozdov in
Google Scholar
PubMed
Search for other papers by Irvin Modlin in
Google Scholar
PubMed
Introduction Biomarker assessment of gastroenteropancreatic neuroendocrine tumor (GEP–NET) disease has been difficult since the default is provided by a monoanalyte measurement, chromogranin A, which has well-described limitations ( Lawrence et al
Search for other papers by Louis de Mestier in
Google Scholar
PubMed
Search for other papers by Clarisse Dromain in
Google Scholar
PubMed
Search for other papers by Gaspard d'Assignies in
Google Scholar
PubMed
Search for other papers by Jean-Yves Scoazec in
Google Scholar
PubMed
Search for other papers by Nathalie Lassau in
Google Scholar
PubMed
Search for other papers by Rachida Lebtahi in
Google Scholar
PubMed
Search for other papers by Hedia Brixi in
Google Scholar
PubMed
Search for other papers by Emmanuel Mitry in
Google Scholar
PubMed
Search for other papers by Rosine Guimbaud in
Google Scholar
PubMed
Search for other papers by Frédéric Courbon in
Google Scholar
PubMed
Search for other papers by Michèle d'Herbomez in
Google Scholar
PubMed
Search for other papers by Guillaume Cadiot in
Google Scholar
PubMed
hypoxia metabolism and might be a potential biomarker of response to antiangiogenic therapy, as reported for sunitinib-treated metastatic renal cell carcinoma ( Hugonnet et al . 2011 ; Fig. 5 ). Figure 5 Axial 18 FMISO-PET views, obtained in a man with